Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.
Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.
复制标题
DOI:
10.1517/17425255.2014.936378
复制
发表时间:
2014-09
影响因子:
4.3
通讯作者:
Cherrington NJ
中科院分区:
文献类型:
--
作者:
Canet MJ;Cherrington NJ
The pharmacokinetics of drugs and xenobiotics, namely pharmaceuticals, is influenced by a host of factors that include genetics, physiological factors, and environmental stressors. The importance of disease on the disposition of xenobiotics has been increasingly recognized among medical professionals for alterations in key enzymes and membrane transporters that influence drug disposition and contribute to the development of adverse drug reactions. This review will survey pertinent literature of how liver disease alters the pharmacokinetics of drugs and other xenobiotics. The focus will be on nonalcoholic steatohepatitis as well as cholestatic liver diseases. A review of basic pharmacokinetic principles, with a special emphasis on xenobiotic metabolizing enzymes and membrane transporters will be provided. Specifically, examples of how genetic alterations affect metabolism and excretion, respectively, will be highlighted. Lastly, the idea of “extra-hepatic” regulation will be explored, citing examples of how disease manifestation in the liver may affect drug disposition in distal sites, such as the kidney. An expert opinion will be provided highlighting the definite need for data in understanding extra-hepatic regulation of membrane transporters in the presence of liver disease and its potential to dramatically alter the pharmacokinetic and toxicokinetic profile of numerous drugs and xenobiotics.